BGT226 | NVP-BGT226 | CAS#1146702-67-1

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

BGT226

Description of BGT226: BGT226 is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BGT226 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability; apoptotic cell death may ensue. Bax is a member of the proapoptotic Bcl2 family of proteins. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer: Novartis.

MedKoo Code#: 200492

Name: BGT226

CAS#: 915020-55-2 (free base); 1245537-68-1 (Maleic acid salt)

Synonym: BTG226; BTG-226; NVP-BGT226.

IUPAC/Chemical name:

8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one

Chemical structure:

Theoretical analysis

Chemical Formula: C28H25F3N6O2

Exact Mass: 534.19911

Molecular Weight: 534.53231

Elemental Analysis: C, 62.91; H, 4.71; F, 10.66; N, 15.72; O, 5.99

Availability and price:

This agent is available through custom synthesis.

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Quality control data:

Product will be shipped with supporting analytical data.

Information about this agent

References

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)